Global Health at Monod Bio

Engineering the future of clinical diagnostics and life sciences tools to solve the world’s most pressing health challenges.

Blue 3D molecular structure hovering over a glowing Earth, symbolizing global biotechnology research.

Spotlight on our global health initiatives

Tuberculosis

Tuberculosis is the world’s deadliest infectious disease, yet diagnosis often relies on sputum, which can be difficult to produce and collect. Testing then requires either insensitive microscopy, slow culture, or resource-intensive molecular methods.

 

Our Approach 

To overcome these barriers, Monod Bio is developing an ultra-sensitive TB-LAM diagnostic. While lipoarabinomannan (LAM) is a critical biomarker for active TB, it is highly fragmented in urine, making it notoriously difficult to detect. We solve this using AI-designed, multispecific and multivalent NovoBody binders. These engineered binders capture diverse LAM fragments with exceptional affinity, delivering lab-level diagnostic precision in a rapid, non-invasive point-of-care test.

 

Preeclampsia

Preeclampsia claims the lives of tens of thousands of women annually, with the burden falling disproportionately on low- and middle-income countries (LMICs) where laboratory infrastructure is limited. Current risk-stratification requires detecting elevated blood pressure and protein in the urine, processes that are often delayed in resource-challenged settings.

 

Our Approach

Monod Bio is developing a rapid, point-of-care diagnostic test for risk-stratification in preeclampsia. Utilizing our hyper-stable biosensors, this test is designed to deliver quantitative, actionable results without the use of central lab equipment, allowing providers to identify high-risk patients before severe symptoms or complications arise.

Other projects coming soon

NovoBody™ Platform: Engineered for Impact in Global Health Diagnostics

  • High Affinity & Avidity: Single-chain format enables precision affinity and avidity with simple manufacturing in bacterial and/or mammalian systems.
  • Rapid Development: Enhanced functionality without long discovery campaigns.
  • Robust Stability: Resistant to harsh chemical conditions and thermodynamic changes, maintaining function in highly variable environments.
  • Customizable Architecture: Flexible formats, including high-affinity, high-valency, and multi-specific constructs.
  • Tailored Properties: Custom-engineered stability, isoelectric points, and site-specific conjugation handles.

Partnering for Global Impact

Tackling global health crises requires collaboration. Monod Bio actively partners with biotechnology, pharmaceutical, global health foundations, and clinical research institutions to bring our biosensors out of the lab and into the field.
Whether it is developing diagnostics for emerging pathogens or democratizing access to crucial biological tools, we are looking for partners who share our vision of an equitable, healthier world.
Contact Monod Bio


Reimagining sFlt-1 & PlGF Immunoassays 

Monod Bio Has Developed Next-Generation NovoBody Pairs Towards sFlt-1 & PLGF

Product launch banner for preeclampsia research tools, including ELISA pairs and NovoBody imagery with a microplate corner.
Poster showing Monod Bio NovoBody platform with sFl-1 & PIGF reagents, ELISA curves, binding schematic, and assay specifications table.

Accelerate your preeclampsia assay development with next-generation AI-designed reagents. Contact our team at partnerships@monod.bio to request an sFlt-1 and/or PlGF ELISA kit or discuss custom sFlt-1 and PlGF NovoBody™ designs. 

 

Let’s Build the Next Generation of Diagnostics Together.

Contact Monod Bio